HUC2 344
Alternative Names: HUC2-344Latest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator Huons
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Diabetes mellitus
Most Recent Events
- 10 Jun 2024 Huons completes a phase I trial in Diabetes mellitus (In volunteers) in South Korea (PO) (NCT06551740, HUC2-344-1_FE)
- 15 Apr 2024 Huons intitates a phase I trial in Diabetes mellitus (In volunteers) in South Korea (PO) (NCT06551740, HUC2-344-1_FE)
- 18 Mar 2024 Huons completes a Phase I trial in Diabetes mellitus (In volunteers) in South Korea (PO) (NCT06552182, HUC2-344-1_FA)